diseaseid CellDeathType Disease pmid Description 481 oxeiptosis Allergies 37612413 List of cell death-related diseases. 482 oxeiptosis allograft rejection 37612413 List of cell death-related diseases. 483 oxeiptosis autoimmunity 37612413 List of cell death-related diseases. 484 oxeiptosis cancer 37612413 List of cell death-related diseases. 485 oxeiptosis colon cancer 35884370 Oxeiptosis is a new type of regulated cell death. Oxeiptosis is independent of caspase. Oxeiptosis is induced by the KEAP1-PGAM5-AIFM1 pathway, which is triggered by ROS. Magnetic hyperthermia and chemotherapy show better effects in colon cancer than single therapy. The type of cell death is presumably oxeiptosis led by ROS in colon cancer, as C-PARP, caspase-3, caspase-8, and c-caspase-8 levels are steady or slightly decreased. 486 oxeiptosis diabetic endothelial dysfunction 37918258 Multiple subroutines covered by RCD may be involved in diabetic endothelial dysfunction, including apoptosis, autophagy, necroptosis, pyroptosis, entosis, ferroptosis, ferroautophagy, parthanatos, netotic cell death, lysosome-dependent cell death, alkaliptosis, oxeiptosis, cuproptosis, and PANoptosis. 487 oxeiptosis hepatocellular carcinoma 37960791 Through multi-omics analysis of OCGs including consensus clustering analysis, functional and signaling pathway enrichment analysis, and tumor microenvironment analysis, our study revealed the possible mechanisms of action of OCGs and provided an accurate and reliable prognostic prediction of HCC by molecular typing and risk scoring model. In addition, the analysis of the tumor microenvironment reveals the mechanisms of immune escape such as T-cell exhaustion, which provides new ideas for subsequent studies. 488 oxeiptosis infection with pathogens 37612413 List of cell death-related diseases. id Symbol Type hgncid name locus_type status entrez_id ensembl_gene_id uniprot_ids 934 PGAM5 oxeiptosis HGNC:28763 PGAM family member 5, mitochondrial serine/threonine protein phosphatase gene with protein product Approved 192111 ENSG00000247077 Q96HS1 935 KEAP1 oxeiptosis HGNC:23177 kelch like ECH associated protein 1 gene with protein product Approved 9817 ENSG00000079999 Q14145 936 AIFM1 oxeiptosis HGNC:8768 apoptosis inducing factor mitochondria associated 1 gene with protein product Approved 9131 ENSG00000156709 O95831 937 AIRE oxeiptosis HGNC:360 autoimmune regulator gene with protein product Approved 326 ENSG00000160224 O43918 938 NRF2 oxeiptosis HGNC:7782 NFE2 like bZIP transcription factor 2 gene with protein product Approved 4780 ENSG00000116044 Q16236 lncid cdtype lncRNA lnctarget pmid description 11422 oxeiptosis MDS2 PGAM5 24297251 starBase v2.0 11423 oxeiptosis NEAT1 PGAM5 24297251 starBase v2.0 11424 oxeiptosis AL627309.5 PGAM5 24297251 starBase v2.0 11425 oxeiptosis LINC02568 PGAM5 24297251 starBase v2.0 11426 oxeiptosis AL355499.2 PGAM5 24297251 starBase v2.0 11427 oxeiptosis ZFPM2-AS1 PGAM5 24297251 starBase v2.0 11428 oxeiptosis DELEC1 KEAP1 24297251 starBase v2.0 11429 oxeiptosis DANCR KEAP1 24297251 starBase v2.0 11430 oxeiptosis MALAT1 KEAP1 24297251 starBase v2.0 11431 oxeiptosis AC144548.1 KEAP1 24297251 starBase v2.0 11432 oxeiptosis AC011511.2 KEAP1 24297251 starBase v2.0 11433 oxeiptosis AL445248.1 KEAP1 24297251 starBase v2.0 11434 oxeiptosis FLJ42969 AIFM1 24297251 starBase v2.0 11435 oxeiptosis MALAT1 AIFM1 24297251 starBase v2.0 11436 oxeiptosis CASC19 AIFM1 24297251 starBase v2.0 11437 oxeiptosis AC138649.1 AIFM1 24297251 starBase v2.0 11438 oxeiptosis JPX AIFM1 24297251 starBase v2.0 11439 oxeiptosis AL627309.5 AIFM1 24297251 starBase v2.0 11440 oxeiptosis NEAT1 AIFM1 24297251 starBase v2.0 11441 oxeiptosis AP001574.1 AIFM1 24297251 starBase v2.0 celldeathtype datasource pathwayname pathwayid intersection_num pathwaygene_num celldeathgenenum genesymbols p_value 1829 oxeiptosis KEGG Ubiquitin mediated proteolysis - Homo sapiens (human) hsa04120 2 142 5 AIRE,KEAP1 0.00049360274882615 1830 oxeiptosis KEGG Mitophagy - animal - Homo sapiens (human) hsa04137 1 103 5 PGAM5 0.0254886601346573 1831 oxeiptosis KEGG Apoptosis - Homo sapiens (human) hsa04210 1 136 5 AIFM1 0.033544042595265 1832 oxeiptosis KEGG Necroptosis - Homo sapiens (human) hsa04217 2 159 5 PGAM5,AIFM1 0.000618277121129052 1833 oxeiptosis KEGG TNF signaling pathway - Homo sapiens (human) hsa04668 1 114 5 PGAM5 0.0281797326465979 1834 oxeiptosis KEGG Hepatocellular carcinoma - Homo sapiens (human) hsa05225 1 168 5 KEAP1 0.0413043634396062 1835 oxeiptosis KEGG Primary immunodeficiency - Homo sapiens (human) hsa05340 1 38 5 AIRE 0.00946491146654493 1836 oxeiptosis KEGG Fluid shear stress and atherosclerosis - Homo sapiens (human) hsa05418 1 139 5 KEAP1 0.0342737002746109 substance_id chemicals cdtype type pmid description 1199 ROS-sensing capabilities oxeiptosis inducer 30342374  we identified oxeiptosis as a novel cellular pathway, which utilizes the ROS-sensing capabilities of KEAP1 to execute a cell-death program 1200 PGAM5 oxeiptosis inducer 30342374  GAM5 does not physically associate with components of the necroptosis pathway, but rather binds to Apoptosis inducing factor 1 (AIFM1), a multifunctional protein that, among other functions, was previously shown to mediate a caspase-independent type of cell death 1201  KEAP1-PGAM5-AIFM1  oxeiptosis inducer 30948788 Oxeiptosis is an oxygen radical-induced form of cell death driven by the activation of the KEAP1-PGAM5-AIFM1 pathway- 1202 H2O2 oxeiptosis inducer 30948788  H2O2 may induce so many different cell death modalities including oxeiptosis,241 apoptosis,242 necrosis,242 and ferroptosis. 1203 Dephosphorylated AIFM1 oxeiptosis inducer 37612413  Dephosphorylated AIFM1 is translocated from mitochondria to the nucleus, where it induces chromatin condensation and DNA fragmentation, leading to cell death 1204 ROS or ROS-generating agents oxeiptosis inducer 37612413 Oxeiptosis is activated in response to oxidative stress induced by ROS or ROS-generating agents, such as viral pathogens.  1205 AIF  oxeiptosis inducer 37612413  Both parthanatos and oxeiptosis involve mitochondrial release of AIF, which is translocated from the mitochondria to the nucleus, resulting in cell death 1206 KEAP1 oxeiptosis inducer 38442446 high levels of H2O2 overactivate KEAP1 leading to the initiation of the oxeiptosis pathway via PGAM5. This may be due to the oxidation of different sets of cysteine residues of KEAP1 by ROS  1207 AIFM1 oxeiptosis inducer 38442446 AIFM1 undergoes dephosphorylation at Serine116 and activates oxeiptosis 1208 KEAP1 oxeiptosis inducer 35321239 At high intracellular ROS levels, KEAP1 and PGAM5 are separated, and PGAM5 enters mitochondria, binds to AIFM1 and dephosphorylates AIFM1 at Ser116, leading to oxeiptosis.  1209 ROS oxeiptosis inducer 37918258 Oxeiptosis is a ROS-induced and caspase-independent non-inflammatory cell death 1210 High intracellular ROS levels  oxeiptosis inducer 38886311 High intracellular ROS levels induce conformational changes in KEAP1, triggering its dissociation from NRF2. KEAP1 translocates into mitochondria and mediates the release of AIFM1 from PGAM5 and AIFM1 translocation to the nucleus, where it dephosphorylates AIFM1 at S116, triggering cell death.  1211 ROS oxeiptosis inducer 35884370 Increased intracellular ROS oxidizes KEAP1, and oxeiptosis is induced. 1212 ozone (O3) or H2O  oxeiptosis inducer 37737953  high concentrations of ozone (O3) or H2O can trigger an apoptosis-like death process called oxeiptosis  1213 KEAP1 oxeiptosis inducer 37737953 Oxeiptosis is mediated by KEAP1, phosphoglycerate mutase family member 5, and apoptosis-inducing factor mitochondrion-associated 1 under oxidative stress [6].  1214 phosphoglycerate mutase family member 5 oxeiptosis inducer 37737953 Oxeiptosis is mediated by KEAP1, phosphoglycerate mutase family member 5, and apoptosis-inducing factor mitochondrion-associated 1 under oxidative stress [6].  1215 apoptosis-inducing factor mitochondrion-associated 1  oxeiptosis inducer 37737953 Oxeiptosis is mediated by KEAP1, phosphoglycerate mutase family member 5, and apoptosis-inducing factor mitochondrion-associated 1 under oxidative stress [6].  1216 ROS  oxeiptosis inducer 32116717 Oxeiptosis is a novel caspase-independent RCD induced by ROS, which is mediated through Kelch-like ECH-associated protein 1 (KEAP1)/PGAM5/apoptosis-inducing factor 1 mitochondrial (AIFM1) pathway 1217 KEAP1 oxeiptosis inhibitor 38442446 In the presence of different concentrations of ROS, KEAP1 showed different roles. In the absence of oxidative stress stimuli, KEAP1 retains Nrf2 in the cytoplasm and ubiquitinates Nrf2 via E3 ligase to degrade it thereby suppressing oxidative stress response gene expression  1218 SNG oxeiptosis inducer 36914635 we demonstrate that sanguinarine (SNG), a quaternary benzophenanthridine alkaloid, induces oxeiptosis in human colorectal cancer (CRC) cells via ROS, specifically hydrogen peroxide (H2O2)-dependent activation of KEAP1-PGAM5-AIFM1 signaling axis. 1219 OI oxeiptosis inducer 37741130 our findings suggest that oxeiptosis of keratinocytes was inhibited in psoriasis and OI can significantly inhibit inflammation and alleviate psoriasis as an agonist of oxeiptosis, indicating that oxeiptosis may be involved in regulating the progression of psoriasis, which may provide new therapeutic targets for psoriasis treatment. 1220 PSNPs oxeiptosis inducer 37466197 our study demonstrated that PSNPs exposure caused oxidative stress, potentially resulting in cell oxeiptosis and senescence to develop haematotoxicity in C57BL/6J mice. 1221 ALT oxeiptosis inducer 37712005 Our findings showed that ALT inhibits the proliferation of skov3 cells in a time and dose dependent manner and IC50 was 32 μM at 24h.A significant down-regulation of Nrf2, GSH and GPX mRNA levels was seen in skov3 cells incubated with 32 and 64 μM of ALT in comparison with control group, while, mRNA expression levels of PGAM5 and KEAP1 were increased.Western blot analysis showed that ALT significantly decreases protein levels of Nrf2 and increases PGAM5 and KEAP1.ALT dephosphorylated PS116-AIFM1 and total AIFM1 protein level was elevated. 1222 MitoQ oxeiptosis inhibitor 36626243 MitoQ may be directly related to mitochondrial biogenesis and has the ability to strengthen mitochondria to maintain the stem cell proliferation and differentiation. Previous studies have suggested that MitoQ regulates PGC1A. In this study, MitoQ was used to dual-regulate and protect the quality of mitochondria. The strategy of handling MitoQ deserves further evaluation and application in the future so that a better understanding is achieved about how to help cells to generate a direct or indirect defense against oxidative stress or improve their repair ability as well as how to overcome the oxidative stress generated by the in vitro culture environment of oocytes and limit the unfavorable factors of cell maturation in vitro. In this context, the provision of clinical artificial reproduction is also of great research value. 1223 Auriculasin oxeiptosis inducer 34872005 Colorectal cancer (CRC) is one of the most common malignant tumors in the digestive system, and Chinese herbal medicine plays an important role in tumor treatment. The in-depth study of auriculasin isolated from Flemingia philippinensis showed that auriculasin promoted reactive oxygen species (ROS) generation in a concentration-dependent manner; when ROS scavenger NAC was added, the effects of auriculasin in promoting ROS generation and inhibiting cell viability were blocked. Auriculasin induced CRC cell apoptosis, led to mitochondrial shrinkage, and increased the intracellular accumulation of Fe2+ and MDA. When auriculasin and NAC were added simultaneously, the levels of apoptosis, Fe2+ and MDA returned to the control group levels, indicating that auriculasin activated apoptosis and ferroptosis by inducing ROS generation. In addition, auriculasin promoted the expression of Keap1 and AIFM1, but significantly reduced the phosphorylation level of AIFM1, while NAC significantly blocked the regulation of Keap1 and AIFM1 by auriculasin, which indicates that auriculasin can also induce oxeiptosis through ROS. When Z-VAD-FMK, Ferrostatin-1, Keap1 siRNA, PGAM5 siRNA and AIFM1 siRNA were added respectively, the inhibitory effect of auriculasin on cell viability was significantly weakened, indicating that auriculasin inhibits cell viability by inducing apoptosis, ferroptosis and oxeiptosis. Auriculasin also inhibited the invasion and clone forming ability of CRC cells, while NAC blocked the above effects of auriculasin. Therefore, auriculasin can promote CRC cell apoptosis, ferroptosis and oxeiptosis by inducing ROS generation, thereby inhibiting cell viability, invasion and clone formation, indicating that auriculasin has a significant antitumor effect. 1224 M-ICG-PTX NPs oxeiptosis inducer 37295777 Insufficient accumulation of drug at the tumor site and the low drug response are the main reason for the unsatisfactory effect of cancer therapy. Delivery drugs exquisitely to subcellular level can be employed to reduce side effects, and expand the therapeutic window. Herein, a triphenylphosphine (TPP) modified lipid nanoparticles is designed which are loaded with the photosensitizer indocyanine green (ICG) and chemotherapeutic paclitaxel (PTX) for mitochondria-targeted chemo-phototherapy. Owing to the movement of majority mitochondria along microtubules in cytoplasm, mitochondrial targeting may enable PTX to act more effectively. Meanwhile, the existence of chemo-drug potentiates the phototherapy to achieve synergistic anti-tumor activity. As expected, mitochondria targeting nanomedicine (M-ICG-PTX NPs) showed improved mitochondria targeted cellular distribution and enhanced cell cytotoxicity in vitro. Also, M-ICG-PTX NPs exhibited higher tumor growth inhibition ability by promoting cell apoptosis and oxeiptosis pathway, and high effective inhibition of primary tumor growth and tumor metastasis. Taken together, M-ICG-PTX NPs may be promising nanoplatforms to achieve potent therapeutic effect for the combination of chemo- and photo-therapy (PTT). 1225 phenethyl isothiocyanate oxeiptosis inducer 37860118 PEITC and dasatinib combination exhibited a synergistic effect in vitro and in vivo. The combination induced DNA damage and oxidative stress through the production of ROS, which led to the formation of a premature CDK1/Cyclin B1 complex associated with induction of mitotic catastrophe. Furthermore, ROS activated oxeiptosis, a caspase-independent form of programmed cell death. 1226 dasatinib oxeiptosis inducer 37860118 PEITC and dasatinib combination exhibited a synergistic effect in vitro and in vivo. The combination induced DNA damage and oxidative stress through the production of ROS, which led to the formation of a premature CDK1/Cyclin B1 complex associated with induction of mitotic catastrophe. Furthermore, ROS activated oxeiptosis, a caspase-independent form of programmed cell death. 1227 APS oxeiptosis inducer 31695464 APS treatment protected the H9C2 cell ultrastructure, reduced the level of cell apoptosis, inhibited cellular ROS production, and reduced the levels of oxidative stress injury indicators 8-OH-dG and nitrotyrosine in high glucose-induced or SOD2-silenced H9C2 cells. It also altered oxidative stress-related genes at the mRNA and protein levels.